World
Russia’s Vaccine Matters to the World
By Kester Kenn Klomegah
President Vladimir Putin has praised the entire healthcare system and particularly the hard-working team of scientists and specialists from different institutions for their efforts at research and creating a series of coronavirus vaccines for use against the coronavirus both at home and abroad.
Three vaccines already registered in Russia, two of them – Sputnik V and EpiVacCorona – are produced in large quantities by Russian pharmaceutical companies and are currently used for vaccination. It is additionally planned to roll out another one – CoviVac.
Despite the pandemic-related challenges, the domestic pharmaceutical companies, in conjunction with research institutes, have managed to accomplish a multitude of objectives in order to deploy new vaccine production sites in a short amount of time, Putin said during a videoconference meeting focused on increasing the manufacturing capacity of COVID-19 vaccines and the progress of vaccination in Russia.
Unreservedly made reference to staff qualities such as consistent and effective hard-work, truly selfless work and responsible attitude, and further urged them to continue making relentless efforts in stabilising the spread of the coronavirus infections and in protecting the life and health of millions of people in the country.
Putin further noted that the implementation of a wide range of preventive measures, including widespread vaccination, has played a significant role in normalising the epidemic situation.
Overall, 6.3 million Russians have taken the first part of the vaccine, of these 4.3 million have been vaccinated in full, that is, they have received both vaccine components.
“We can safely say, and the practical results indisputably corroborate, the fact that the Russian vaccines are absolutely safe and dependable. Our success is recognised abroad as well. The number of countries using the Sputnik V vaccine is expanding fast, more countries around the world are showing interest in our vaccine with 55 countries having authorised its use,” he told the meeting.
In addition, Russia now has a number of contracts with foreign manufacturers, – these are foreign manufacturers who will be producing our vaccine on their territory – have been signed for the number of doses needed to vaccinate 700 million people per year.
The latest, it has signed a contract with an Indian company for doses to vaccinate 100 million people. Indisputably, working with 55 countries means a total population of 1.4 billion. There are plans to expand the number of partner countries and that will reach an estimated 2.5 billion people.
While Russia and its pharmaceutical companies are considering the dynamics of the global market and the demand for Russian-made vaccines, and expanding their production capacities, it equally places emphasis on domestic needs, supplying and vaccinating Russian citizens with vaccines, is an absolute priority.
It is estimated that at least 60 per cent of all adults in the country must be vaccinated for complete stabilisation. This requires 69.8 million sets of vaccine doses. At any rate, there are more than 20 million Sputnik V doses, according to the Russian president, quoting his Prime Minister Mikhail Mishustin.
In his contribution at the meeting, Minister of Industry Denis Manturov informed that under the plan, 12.5 million sets of the vaccine must be produced in March. The planned figure for April is 17 million. It is planned to continue building up production so as to have over 80 million two-component doses by the first six months.
According to him, all these amounts will be primarily used to vaccinate Russian citizens. In order to meet the global demand for Russian vaccines, his ministry is working on scaling up the production of vaccines and on transferring technology abroad. It already has comprehensive agreements on this with manufacturers in 10 countries.
Healthcare Minister Mikhail Murashko informed the meeting about organisations that keep monitoring the virus’s mutations, including those in Russia. “We are analysing the efficiency of medicines for preventing the disease caused by various strains. This work is ongoing continuously and involves several agencies,” he said, and further mentioned the need to increase the speed of vaccination.
By the end of March, our healthcare facilities will receive over 6.5 million doses of Sputnik V. We expect that a total of some 30 million doses will be delivered in April and May. As of now, there are 4,500 stationary vaccination stations across Russia and plans to increase this figure, as well as over 1,000 mobile stations.
Participating in the meeting, Pharmstandard Chairman of the Board Viktor Kharitonin also discussed the production capability of the vaccine and pointed to the successful completion of the transfer of laboratory technology, scaled and fine-tuned the manufacturing technology abroad.
“It should be specifically pointed out that, thanks to our cooperation with the Russian Direct Investment Fund, we have started supplying the vaccine to foreign markets. We have already transferred the production technology to Kazakhstan and Belarus and continue working with other countries, including India and Italy. In Italy, Sputnik V was highly praised by both scientists and our colleagues from pharmaceutical companies,” added Kharitonin.
Taking his turn, Chairman of the Board of the R-Pharm Group Alexei Repik talked about efforts that are currently focused on the creation and manufacturing of new forms of the vaccine that will be easier to use and also to transport. He noted that it will increase the attractiveness of the vaccines on foreign markets, including countries with a hot climate: the Middle East, Africa and Latin America.
“Our factory is now producing the first registration batches of a promising lyophilic form of the vaccine created by our experts. It has proved stable at temperatures between +2 and +8 C. We are now studying its stability at room temperature. There are grounds to believe that we will succeed. This form will allow us to make the vaccine available in hard-to-reach regions of the country, which is especially important ahead of the spring and summer period,” informed Alexei Repik.
Director of the Gamaleya National Research Centre for Epidemiology and Microbiology Alexander Gintsburg also highlighted a few aspects of the vaccine production and about documents for registration. According to him, the Gamaleya Research Centre also addresses the problem of expanding the production of the Sputnik Light vaccine.
In addition, as the holder of the registration certificate, the Centre assumes all responsibility for quality control of this vaccine at all enterprises where it is manufactured in this country and abroad.
Moreover, the Centre is directly involved in launching contractual production that is mostly organised by the Russian Direct Investment Fund. The Centre has prepared the entire package of documents for registering the Sputnik Light vaccine in 55 countries. Considering that each country has its own regulatory system, this is not a fixed package of documents that will apply everywhere, therefore it has to adapt it to every country’s regulatory system.
He further spoke about The Lancet, a highly prestigious and popular medical journal, that published two articles on the results of scientific data and clinical trials. This provides important scientific evidence proving the vaccine’s efficacy, this has completely eliminated the Western academic community’ scepticism regarding the vaccines’ quality and efficacy.
Alexander Gintsburg explained a little about children’s vaccination. According to him, children must be divided into several age groups. Russian experts and specialists in paediatric immunology are working in this direction. He said that a vaccine has been developed, patented, and are currently launching clinical trials of Sputnik V’s intranasal form. This is a very gentle and patient-friendly form of vaccination for children, especially little children, who can be traumatised when they see a syringe or when possible side effects arise. The first experiments show that the intranasal form is completely free from any side effects.
CEO of the Russian Direct Investment Fund (RDIF) Kirill Dmitriev stressed patent protection and protecting intellectual rights for Russian made vaccines and other medical products. “Our patent protection is very strong. We submitted applications early on, much earlier than other countries, and thus got a headstart. Accordingly, the Gamaleya Institute owns the innovations that are available even at these foreign sites, which include over 20 partner companies in 10 countries,” he told the meeting.
On foreign cooperation, “Mr President, I would like to thank you, because it was your idea to build production partnerships with various countries, and 20 manufacturers from over 10 countries responded. For them, it’s about vaccine safety and independence, and Russia was the only country to have come up with this offer. Thank you very much. They are very grateful to you for this,” Kirill Dmitriev said in appreciation.
Director-General of the Vektor State Research Centre of Virology and Biotechnology Rinat Maksyutov discussed various research operations. Vektor is the only WHO COVID-19 reference laboratory in Russia. It not only conducts the entire range of viral studies of the novel coronavirus but is also monitoring its genetic mutations across the country on a regular basis.
“By now, we have found over 5,300 genetic variations across the genome. In the overwhelming number of cases, the replacement does not change the epidemiological characteristics of the virus. At the same time, we have also found over 50 variations of the British strain, three cases of the South African strain and over 20 unique variations of the virus that must be thoroughly studied,” he said.
According to Rinat Maksyutov, the Research Centre Vektor is studying these variations of the virus in accordance with a special algorithm. “We are studying the virus’s stability on various surfaces; we are also using unique equipment, which has no analogues throughout the world, to study the ability of the virus to be transmitted between living organisms. We have found that the British strain of the novel coronavirus can be effectively neutralised by serum taken from those who had COVID and those vaccinated with Sputnik V or EpiVacCorona,” he told the meeting.
Director-General of the Chumakov Federal Scientific Centre for the Research and Development of Immune and Biological Products (Russian Academy of Sciences) Aidar Ishmukhametov spoke about their engagement and involvement in research and production of medical products, tracing its roots to the Soviet Union.
The Chumakov Centre is one of the oldest facilities in the Russian Federation and the oldest vaccine developer in Russia. That in the 1960s, this centre’s achievements helped the country deal with polio. The centre back then developed a unique vaccine that supplied to the entire world, including the United States, Europe, Japan and many other countries. In fact, now this facility, the Institute of Poliomyelitis, is well-known around the world.
It is continuing this tradition. As of today, it has developed and produced five vaccines, including for tick-borne encephalitis, rabies and the yellow fever vaccine that is supplied to almost 50 countries, which is perhaps Russia’s biggest export in the pharmaceutical industry.
This type of organisation that has a research and development facility at its core that can outline the task and release a certain number of batches of the vaccine consisting of tens of millions [of doses], on one hand, and well-coordinated work with research institutes and the search for partners, on the other hand, is a very efficient model.
“We did not intend to work exclusively on the coronavirus vaccine. It was important to us to maintain the same production volume and supply vaccines according to the national vaccination calendar as well as deliver on the exports. So we needed to fit this new objective into our existing model. We inherited this research and development facility from the Soviet Union where it was a leader in this industry, and we are developing it,” he underlined the importance of his institution at the meeting.
CEO of the National Immunobiological Company, Rostec State Corporation, Andrei Zagorsky, however, noted that vaccine production is growing steadily. He highlighted the question of warehousing (storage), freezer facility and shipping to the regions. This is carried out in close cooperation with the manufacturing sites, as well as cargo recipients in the regions. These tasks are fulfilled on schedule, he said.
“We monitor the entire production process, especially the temperature, all the way from production, transport, acceptance to a warehouse, storage at the warehouse, to shipment to a recipient region. All products are transported in thermal containers, which can keep temperatures at 18 degrees below zero Celsius for about five days,” he added, speaking at the meeting.
Deputy Prime Minister Tatyana Golikova concluded with high appreciation. The meeting ended with a clear understanding of what direction should be moving to overcome the coronavirus pandemic and at the same time, extend assistance to foreign countries that are in need.
She, however, reiterated that, in a fairly short time, despite the difficulties and amid the challenging pandemic of 2020, all her colleagues have indeed accomplished something that seemed almost impossible, worked 24/7 and made Russia the leader in the production and use of vaccines, primarily, for the public in Russia.
Kester Kenn Klomegah is a versatile researcher and a passionate contributor. Most of his well-resourced articles are reprinted elsewhere in a number of reputable foreign media.
World
Today’s Generation of Entrepreneurs Value Flexibility, Autonomy—McNeal-Weary
By Kestér Kenn Klomegâh
The Young African Leaders Initiative (YALI) is the United States’ signature step to invest in the next generation of African leaders. Since its establishment in 2010 by Obama administration, YALI has offered diverse opportunities, including academic training in leadership, governance skills, organizational development and entrepreneurship, and has connected with thousands of young leaders across Africa. This United States’ policy collaboration benefits both America and Africa by creating stronger partnerships, enhancing mutual prosperity, and ensuring a more stable environment.
In our conversation, Tonya McNeal-Weary, Managing Director at IBS Global Consulting, Inc., Global Headquarters in Detroit, Michigan, has endeavored to discuss, thoroughly, today’s generation of entrepreneurs and also building partnerships as a foundation for driving positive change and innovation in the global marketplace. Here are the excerpts of her conversation:
How would you describe today’s generation of entrepreneurs?
I would describe today’s generation of entrepreneurs as having a digital-first mindset and a fundamental belief that business success and social impact can coexist. Unlike the entrepreneurs before them, they’ve grown up with the internet as a given, enabling them to build global businesses from their laptops and think beyond geographic constraints from day one. They value flexibility and autonomy, often rejecting traditional corporate ladders in favor of building something meaningful on their own terms, even if it means embracing uncertainty and financial risk that previous generations might have avoided.
And those representing the Young African Leaders Initiative, who attended your webinar presentation late January 2026?
The entrepreneurs representing the Young African Leaders Initiative are redefining entrepreneurship on the continent by leveraging their unique perspectives, cultural heritage, and experiences. Their ability to innovate within local contexts while connecting to global opportunities exemplifies how the new wave of entrepreneurs is not confined by geography or conventional expectations.
What were the main issues that formed your ‘lecture’ with them, Young African Leaders Initiative?
The main issues that formed my lecture for the Young African Leaders Initiative were driven by understanding the importance of building successful partnerships when expanding into the United States or any foreign market. During my lecture, I emphasized that forming strategic alliances can help entrepreneurs navigate unfamiliar business environments, access new resources, and foster long-term growth. By understanding how to establish strong and effective partnerships, emerging leaders can position their businesses for sustainable success in global markets. I also discussed the critical factors that contribute to successful partnerships, such as establishing clear communication channels, aligning on shared goals, and cultivating trust between all parties involved. Entrepreneurs must be proactive in seeking out partners who complement their strengths and fill gaps in expertise or resources. It is equally important to conduct thorough due diligence to ensure that potential collaborators share similar values and ethical standards. Ultimately, the seminar aimed to empower YALI entrepreneurs with practical insights and actionable strategies for forging meaningful connections across borders. Building successful partnerships is not only a pathway to business growth but also a foundation for driving positive change and innovation in the global marketplace.
What makes a ‘leader’ today, particularly, in the context of the emerging global business architecture?
In my opinion, a leader in today’s emerging global business architecture must navigate complexity and ambiguity with a fundamentally different skill set than what was previously required. Where traditional leadership emphasized command-and-control and singular vision, contemporary leaders succeed through adaptive thinking and collaborative influence across decentralized networks. Furthermore, emotional intelligence has evolved from a soft skill to a strategic imperative. Today, the effective modern leader must possess deep cross-cultural intelligence, understanding that global business is no longer about exporting one model worldwide but about genuinely integrating diverse perspectives and adapting to local contexts while maintaining coherent values.
Does multinational culture play in its (leadership) formation?
I believe multinational culture plays a profound and arguably essential role in forming the kind of leadership required in today’s global business environment. Leaders who have lived, worked, or deeply engaged across multiple cultural contexts develop a cognitive flexibility that’s difficult to replicate through reading or training alone. More importantly, multinational exposure tends to dismantle the unconscious certainty that one’s own way of doing things is inherently “normal” or “best.” Leaders shaped in multicultural environments often develop a productive discomfort with absolutes; they become more adept at asking questions, seeking input, and recognizing blind spots. This humility and curiosity become strategic assets when building global teams, entering new markets, or navigating geopolitical complexity. However, it’s worth noting that multinational experience alone doesn’t automatically create great leaders. What matters is the depth and quality of cross-cultural engagement, not just the passport stamps. The formation of global leadership is less about where someone has been and more about whether they’ve developed the capacity to see beyond their own cultural lens and genuinely value differences as a source of insight rather than merely tolerating them as an obstacle to overcome.
In the context of heightening geopolitical situation, and with Africa, what would you say, in terms of, people-to-people interaction?
People-to-people interaction is critically important in the African business context, particularly as geopolitical competition intensifies on the continent. In this crowded and often transactional landscape, the depth and authenticity of human relationships can determine whether a business venture succeeds or fails. I spoke on this during my presentation. When business leaders take the time for face-to-face meetings, invest in understanding local priorities rather than imposing external agendas, and build relationships beyond the immediate transaction, they signal a different kind of partnership. The heightened geopolitical situation actually makes this human dimension more vital, not less. As competition increases and narratives clash about whose model of development is best, the businesses and nations that succeed in Africa will likely be those that invest in relationships characterized by reciprocity, respect, and long-term commitment rather than those pursuing quick wins.
How important is it for creating public perception and approach to today’s business?
Interaction between individuals is crucial for shaping public perception, as it influences views in ways that formal communications cannot. We live in a society where word-of-mouth, community networks, and social trust areincredibly important. As a result, a business leader’s behavior in personal interactions, their respect for local customs, their willingness to listen, and their follow-through on commitments have a far-reaching impact that extends well beyond the immediate meeting. The geopolitical dimension amplifies this importance because African nations now have choices. They’re no longer dependent on any single partner and can compare approaches to business.
From the above discussions, how would you describe global business in relation to Africa? Is it directed at creating diverse import dependency?
While it would be too simplistic to say global business is uniformly directed at creating import dependency, the structural patterns that have emerged often produce exactly that outcome, whether by design or as a consequence of how global capital seeks returns. Global financial institutions and trade agreements have historically encouraged African nations to focus on their “comparative advantages” in primary commodities rather than industrial development. The critical question is whether global business can engage with Africa in ways that build productive capacity, transfer technology, develop local talent, and enable countries to manufacture for themselves and for export—or whether the economic incentives and power irregularities make this structurally unlikely without deliberate policy intervention.
World
Russia Expands Military-Technical Cooperation With African Partners
By Kestér Kenn Klomegâh
Despite geopolitical complexities, tensions and pressure, Russia’s military arms and weaponry sales earned approximately $15 billion at the closure of 2025, according to Kremlin report. At the regular session, chaired by Russian President Vladimir Putin on Jan. 30, the Commission on Military and Technical Cooperation with Foreign Countries analyzed the results of its work for 2025, and defined plans for the future.
It was noted that the system of military-technical cooperation continued to operate in difficult conditions, and with increased pressure from the Western countries to block business relations with Russia. The meeting, however, admitted that export contracts have generally performed sustainably. Russian military products were exported to more than 30 countries last year, and the amount of foreign exchange exceeded $15 billion.
Such results provide an additional opportunity to direct funds to the modernization of OPC enterprises, to the expansion of their production capacities, and to advanced research. It is also important that at these enterprises a significant volume of products is civilian products.
The Russian system of military-technical cooperation has not only demonstrated effectiveness and high resilience, but has created fundamental structures, which allow to significantly expand the “geography” of supplies of products of military purpose and, thus strengthen the position of Russia’s leader and employer advanced weapons systems – proven, tested in real combat conditions.
Thanks to the employees of the Federal Service for Military Technical Cooperation and Rosoboronexport, the staff of OPC enterprises for their good faith. Within the framework of the new federal project “Development of military-technical cooperation of Russia with foreign countries” for the period 2026-2028, additional measures of support are introduced. Further effective use of existing financial and other support mechanisms and instruments is extremely important because the volumes of military exports in accordance with the 2026 plan.
Special attention would be paid to the expansion of military-technological cooperation and partnerships, with 14 states already implementing or in development more than 340 such projects.
Future plans will allow to improve the characteristics of existing weapons and equipment and to develop new promising models, including those in demand on global markets, among other issues – the development of strategic areas of military-technical cooperation, and above all, with partners on the CIS and the CSTO. This is one of the priority tasks to strengthen both bilateral and multilateral relations, ensuring stability and security in Eurasia.
From January 2026, Russia chairs the CSTO, and this requires working systematically with partners, including comprehensive approaches to expanding military-technical relations. New prospects open up for deepening military-technical cooperation and with countries in other regions, including with states on the African continent. Russia has been historically strong and trusting relationships with African countries. In different years even the USSR, and then Russia supplied African countries with a significant amount of weapons and military equipment, trained specialists on their production, operation, repair, as well as military personnel.
Today, despite pressure from the West, African partners express readiness to expand relations with Russia in the military and military-technical fields. It is not only about increasing supplies of Russian military exports, but also about the purchase of other weapons, other materials and products. Russia has undertaken comprehensive maintenance of previously delivered equipment, organization of licensed production of Russian military products and some other important issues. In general, African countries are sufficient for consideration today.
World
Trump Picks Kevin Warsh to Succeed Jerome Powell as Federal Reserve Chair
By Adedapo Adesanya
President Donald Trump has named Mr Kevin Warsh as the successor to Mr Jerome Powell as the Federal Reserve chair, ending a prolonged odyssey that has seen unprecedented turmoil around the central bank.
The decision culminates a process that officially began last summer but started much earlier than that, with President Trump launching a criticism against the Powell-led US central bank almost since he took the job in 2018.
“I have known Kevin for a long period of time, and have no doubt that he will go down as one of the GREAT Fed Chairmen, maybe the best,” Mr Trump said in a Truth Social post announcing the selection.
US analysts noted that the 55-year old appear not to ripple market because of his previous experience at the apex bank as Governor, with others saying he wouldn’t always do the bidding of the American president.
If approved by the US Senate, Mr Warsh will take over the position in May, when Mr Powell’s term expires.
Despite having argued for reductions recently, “Warsh has a long hawkish history that markets have not forgotten,” one analyst told Bloomberg.
President Trump has castigated Mr Powell for not lowering interest rates more quickly. His administration also launched a criminal investigation of Powell and the Federal Reserve earlier this month, which led Mr Powell to issue an extraordinary rebuke of President Trump’s efforts to politicize the independent central bank.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism9 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn











